Highest-materiality recent filing
Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.
Precision BioSciences shareholders approve 3.8M share increase for equity plan; elect directors
Shareholders approved amendment to 2019 Incentive Award Plan, increasing share reserve by 3.8M shares (58% for, 42% against).
Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing
Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.
Precision BioSciences hosts KOL event for PBGENE-DMD DMD program; no new data disclosed
KOL event on March 17, 2026 features Dr. Veerapandiyan and Pat Furlong discussing DMD unmet need and treatment landscape.
Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).
FDA clears Precision BioSciences' IND for PBGENE-DMD gene editing therapy for DMD
FDA Study May Proceed allows initiation of clinical trial site activation for Phase 1/2 FUNCTION-DMD study in ambulatory DMD patients.
Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.
Precision BioSciences prices $75M underwritten offering of common stock and warrants
Offering: 10.8M shares + 1.4M pre-funded warrants at $6.14/$6.139995 per unit; gross proceeds ~$75M.
Phase 1 ELIMINATE-B trial: 9 patients across 0.2, 0.4, 0.8 mg/kg doses (22 total administrations); no dose-limiting toxicities observed.
Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.
Amended agreements with CEO Michael Amoroso, CFO Alex Kelly, GC Dario Scimeca, and CRO Jeff Smith.
Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients
Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).
Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027
Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.
Precision BioSciences' charter amendment for officer exculpation fails at annual meeting
Kevin J. Buehler and Shari Lisa Piré elected as Class III directors.
Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated
Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.
Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243
PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.
Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction
Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.
Precision BioSciences reshuffles director classes, cuts board to six members
Board reclassified Michael Amoroso from Class I to Class II director.
Director Sam Wadsworth retires from Precision BioSciences board
Sam Wadsworth, Ph.D., resigned from Board of Directors effective January 23, 2025.
Preliminary unaudited cash, cash equivalents, and restricted cash of ~$108.5M as of Dec 31, 2024, before $2.5M TG payment in Jan 2025.
Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic
Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.
Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova
Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).
Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.
Precision BioSciences receives $9.75M cash + $3.25M Imugene shares from convertible note maturity
Convertible note from August 2023 azer-cel deal with Imugene matured; Precision receives $9.75M cash and $3.25M in Imugene ordinary shares.
Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024
Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.
Precision BioSciences shareholders approve increase of 630,000 shares in incentive plan
Shareholders elected Stanley R. Frankel, M.D. and Samuel Wadsworth, Ph.D. as Class II directors for term until 2027.
Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026
Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.
Precision BioSciences sells 25,000 shares at $12 to management in private placement
Gross proceeds ~$300k from sale of 25,000 shares at $12.00/share (13.5% premium to prior day close).
Prevail (Lilly sub) terminated collaboration without cause effective July 10, 2024; Precision exercised reversion option to regain programs.
Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026
FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.
Precision BioSciences prices $40M public offering of 2.5M shares and warrants at $16/unit
Offering of 2,500,000 common shares and warrants to purchase another 2,500,000 shares at $16.00 per unit.
Precision BioSciences effects 1-for-30 reverse stock split effective Feb 13, 2024
Reverse stock split at 1-for-30 ratio effective 5:00 p.m. ET on February 13, 2024.
Precision BioSciences enters new exec employment agreements with enhanced severance
CEO Michael Amoroso: 18-month salary severance, 1.5x target bonus, 25-month equity acceleration.
Approximately 68.34% of common shares represented at special meeting on January 18, 2024.
Precision grants TG Therapeutics exclusive license for non-oncology applications of azer-cel, receiving $17.5M in upfront and near-term payments.
Precision BioSciences amends bylaws for universal proxy and nomination procedures
Board adopted amended bylaws on Dec 19, 2023, effective same day, addressing SEC universal proxy rules.
On January 23, 2025, Sam Wadsworth, Ph.D., notified Precision BioSciences, Inc. (the “Company”) of his intention to retire from service on company boards and resigned from the Company’s Board of Directors.
On September 9, 2024, Alan List, M.D., the Company’s Chief Medical Officer, notified Precision BioSciences, Inc. (the “Company”) that he will be retiring from the Company, effective September 13, 2024.
Max materiality 0.90 · Median 0.70 · Most common event other_material